News | September 23, 2024
AstraZeneca Pharma India to launch Tremelimumab
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
The conference aims to bring various stakeholders and experts in the field of healthcare and digital solutions for ensuring ‘universal access to affordable and quality healthcare’
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Subscribe To Our Newsletter & Stay Updated
